XIAP and prostate carcinoma: The results are consistent with previous reports showing that the down-regulation of XIAP sensitizes cancer cells to therapeutic drugs in lung cancer, prostate cancer, ovarian cancer and pancreatic cancer[14], [15], [16], [17], [18], [19], [20].